HomeProductsBioactive CompoundsMetabolic EnzymesPDEAnagrelide
Chemical structure of CAS 68475-42-3

Anagrelide

In Stock•Starting at $19 for 1 mg•Purity ≥ 98%
CAS No.68475-42-3
MDL No.MFCD00866794
MFC10H7Cl2N3O
MW256.08
InChI KeyOTBXOEAOVRKTNQ-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98%$19In Stock
5 mg98%$50In Stock
10 mg98%$83In Stock
25 mg98%$163In Stock
50 mg98%$243In Stock
100 mg98%$434In Stock
250 mg98%$865In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Anagrelide is a 1,5-dihydroimidazo[2,1-]quinazoline with an oxo group at the 2-position and chloro groups at the 6- and 7-positions. It functions as an anticoagulant, platelet aggregation inhibitor, antifibrinolytic drug, and cardiovascular agent.

CAS No.68475-42-3
Product NameAnagrelide

Biological Targets

PDE3A·PDE3B

Associated Conditions

neoplasm·myeloproliferative disorder·polycythemia vera·essential thrombocythemia·thrombotic disease·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Long-term use of anagrelide in young patients with essential thrombocythemia.

Blood • Vol. 97, Issue 4 • 2001
PMID: 11159509DOI: 10.1182/blood.v97.4.863

Current management in polycythemia vera.

Seminars in hematology • Vol. 38, Issue 1 Suppl 2 • 2001
PMID: 11242599DOI: 10.1016/s0037-1963(01)90137-4

Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.

Pathologie-biologie • Vol. 49, Issue 2 • 2001
PMID: 11317960DOI: 10.1016/s0369-8114(00)00020-1

Management of patients with essential thrombocythemia: current concepts and perspectives.

Pathologie-biologie • Vol. 49, Issue 2 • 2001
PMID: 11317966DOI: 10.1016/s0369-8114(00)00026-2

Documentation

Similar Products